Conference Program
08:30-17:00
Registration
09:30-09:40
Welcome & Opening Remarks
Alexander M.M. Eggermont, MD, PhD | Congress Chair
09:40-10:45
Session 1: Non-Invasive Diagnostics, Dermatopathology and Artificial Intelligence
09:40-10:05
Diagnostics Using Non-Invasive Technologies in Dermatological Oncology
10:05-10:30
Artificial Intelligence outperforms classic histopathology in skin cancer diagnosis
10:30-10:45
Discussion/ Q&A
10:45-11:15
Coffee Break, Poster Viewing & Visit the Exhibition
11:15-12:15
Session 2: Prevention of skin cancers: fact or fiction, limitations vs opportunities
11:15-11:35
Prevention and screening of melanoma in Europe: 20 years of the Euromelanoma campaign
11:35-12:00
Prevention of skin cancers: fact or fiction, limitations vs opportunities
12:00-12:15
Discussion/ Q&A
12:15-12:30
Session 3: Short Presentations by Young Investigators
12:30-13:30
Lunch Break, Poster Viewing & Visit the Exhibition
13:30-14:30
Session 4: Melanoma Staging under Scrutiny, current & future developments
13:30-13:55
Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy
13:55-14:15
CP-GEP as a tool to identify risk of relapse in stage I/II and Head & Neck Melanoma populations
14:15-14:30
Discussion/ Q&A
14:30-14:45
Session 5: Short Presentations By Young Investigators
14:45-15:15
Coffee Break, Poster Viewing & Visit the Exhibition
15:15-16:45
Session 6: What is New in Rare Malignancies
15:15-15:40
What’s new in Cutaneous T Cell Lymphoma?
15:40-16:05
What’s new in Merkel Cell Carcinoma?
16:05-16:30
What’s new Uveal Melanoma?
16:30-16:45
Discussion/ Q&A
16:45-17:15
Session 7: Microbiome and Immunotherapy
16:45-17:15
Microbiome and Immunotherapy
17:15
End of Day One
08:30
Registration
09:00-10:30
Session 8: Adjuvant and Neoadjuvant therapy in Dermato-Oncology
09:00-09:30
Adjuvant Therapy of Melanoma and the Role for Identifiers of High Risk for Relapse: Consequences for New Trials and Daily Practice
09:30-10:00
Neoadjuvant Immunotherapy the Standard for Stage III and beyond?
10:00-10:20
Neoadjuvant or Adjuvant Therapy in NMSC for which populations?
10:20-10:30
Discussion/ Q&A
10:30-11:00
Coffee Break, Poster Viewing & Visit the Exhibition
11:00-12:00
Session 9: Prediction, Registration and Management of irAEs C
11:00-11:25
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
11:25-11:50
The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
11:50-12:00
Discussion/ Q&A
12:00-12:15
Session 10: Short Presentations By Young Investigators
12:15-13:15
Lunch Break, Poster Viewing & Visit the Exhibition
13:15-15:15
Session 11: New Strategies in Advanced Melanoma Part I
13:15-13:40
New Developments/New Drugs and Strategies in Targeted therapies for Melanoma and NMSC
13:40-14:05
New developments to overcome resistance to targeted therapies
14:05-15:05
Prediction of PD1-Senstitive and PD1-Refractory Patients with Advanced Melanoma: Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
15:05-15:15
Discussion/ Q&A
15:15-15:45
Coffee Break, Poster Viewing & Visit the Exhibition
15:45-17:20
Session 12: New Strategies in Advanced Melanoma Part II
15:45-16:10
Cytolytic Vaccines and New Vaccines for Melanoma: what is new and most promising?
16:10-16:35
Cellular Therapies, Bispecific Moabs and T-Gell engagers
16:35-17:00
From IO Doublet Combos to Triplet Combos in Immunotherapy of Advanced Melanoma
17:00-17:10
Discussion/ Q&A
17:10-17:20
Poster Award Ceremony / Conclusions and Closure
17:20
End of Congress